Anesiva Inc

Anesiva — AlgoRx Pharmaceuticals — Merger or Acquisition (October 2005)

13 slides from Anesiva's merger presentation, Oct 5, 2005

  1. Slide 1: ALGRX 3268 Phase 3 Results

    ALGRX 3268 PHASE 3 RESULTS October 5, 2005

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “pla

  3. Slide 3: Forward Looking Statements (2)

    FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involv

  4. Slide 4: Product Pipeline

    PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALGRX Pre-procedural analgesia (003) Pre-procedural analgesia (004) ALGRX 4975 * Post-surgical pain Morton’s neuroma Tendonitis NF- K B Decoy * Atopic dermatitis (eczema) ALGRX 1207 * Cutaneous neuropathic pain * Does not reflect comprehensive lis

  5. Slide 5: ALGRX 3268 - Topical Local Anesthesia

    ALGRX 3268- TOPICAL LOCAL ANESTHESIA Indication Reduction of pain associated with venipunctures and intravenous line placements Two Phase 3 trials being conducted Key desirable product attributes Sterile, pre-filled, needle-free disposable delivery system (Powderject®) Rapid onset of action Within 1

  6. Slide 6: Reduction in Pain from Venipuncture after Administration

    ALGRX 3268 Reduction in Pain from Venipuncture after Administration EMLA Package Insert for EMLA VAS, mm 10 0 -10 -20 -30 60 Time after administration, minutes VAS, mm 10 0 - -10 -20 -30 ALGRX 3268 Data from Phase 1 trial in 272 adults 3 5 Time after administration, minutes ALGRX 3268 has an onset w

  7. Slide 7: ALGRX 3268 Development

    ALGRX 3268 DEVELOPMENT Protocol Age Group Phase Total Patients Primary Endpoint Status Antecubital Fossa Adults 1 272 Safety and Efficacy Primary Endpoint Achieved Back of Hand Adults 1 183 Safety and Efficacy Primary Endpoint Achieved Pharmacokinetics Adults 1 38 Evaluate Circulating Lidocaine Prim

  8. Slide 8: Phase 3 Trials: Identical Protocols

    PHASE 3 TRIALS: 003 AND 004 IDENTICAL PROTOCOLS Design U.S. multicenter, randomized, double-blind, placebo-controlled Number of subjects 500 - 600 subjects in each study Population Pediatric subjects of either gender (ages 3-18) Objectives Confirm efficacy, safety and tolerability of ALGRX 3268 vs.

  9. Slide 9: Phase 3 Results (Trial 003)

    PHASE 3 RESULTS (TRIAL 003) Primary endpoint achieved (p=0.007) Statistically significantly less pain on needle insertion in treated group compared to placebo group assessed using FACES rating scale 574 patients at six U.S. clinical trial sites ALGRX 3268 group = 289 patients (ages 3-18) Placebo = 2

  10. Slide 10: Projected Timeline for ALGRX 3268

    PROJECTED TIMELINE FOR ALGRX 3268 Clinical Data from second Phase 3 trial (004) expected within two months Regulatory Reviewed as a drug by the FDA Analgesics and Acute Care Division Registration File NDA in 1H06 Product approval in 1H07

  11. Slide 11: Underserved Market

    UNDERSERVED MARKET Target market Only 2.1MM out of 18MM venipuncture procedures in children’s hospitals and large academic institutions utilize a topical local anesthetic today Low utilization of topical local anesthetics (12% of pediatric procedures) due to slow onset of action lack of promotion of

  12. Slide 12: ALGRX 3268: Phased Marketing Approach

    3268: PHASED MARKETING APPROACH Physician Offices, Labs, Blood Donation Centers Hemodialysis Centers In-hospital Adult (ER) In-hospital Pediatric 18M

  13. Slide 13: Thank you for participating on today's call

    Thank you for participating on today’s call. For additional information about the proposed merger of Corgentech and AlgoRx, please visit www.corgentech.com and the other sources described in our forward looking statement slide

AlgoRx Pharmaceuticals — Merger or Acquisition (October 2005) on 6ix